Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?
July 16, 2019
This review summarizes the major clinical trials that led to the approval of antiangiogenic drugs for ovarian cancer and gives a brief view into novel combinations of bevacizumab with other targeted therapies in an attempt to enhance the efficacy of bevacizumab.
